user avatar
Paolo Tarantino
@PTarantinoMD
MD, PhD, Medical Oncologist | Clinical Fellow @DanaFarber | @Harvard. Associate Editor @ESMO_Open. Interested in breast oncology, HER2, ADCs and good music.
Boston, MA
Joined January 2018
788
Following
31.6K
Followers
Posts
  • Pinned
    user avatar
    Paolo Tarantino
    @PTarantinoMD
    Jun 9, 2023
    ADCs enable an improved delivery of chemo, expanding its activity, but not necessarily decreasing its side effects. Why is that? How can we reduce the toxicities of ADCs? Glad to share our @NatRevClinOncol article on how to optimize the safety of ADC! 🧵 nature.com/articles/s4157…
    104K
  • user avatar
    Paolo Tarantino
    @PTarantinoMD
    Aug 22, 2022
    Out-of-office with limited access to the email.
  • user avatar
    Paolo Tarantino
    @PTarantinoMD
    Dec 8, 2021
    🇮🇹 Milan, today
  • user avatar
    Paolo Tarantino
    @PTarantinoMD
    May 29, 2021
    Discussing upcoming #ASCO21 abstracts with colleagues - the 🇮🇹 way #BackHome #AmalfiCoast
  • user avatar
    Paolo Tarantino
    @PTarantinoMD
    Jun 5, 2022
    Standing ovation after the #ASCO22 Plenary presentation of DESTINY-Breast04 by Dr. Shanu Modi. A beautiful, powerful moment, that will remain in the history of breast oncology.
  • user avatar
    Paolo Tarantino
    @PTarantinoMD
    Jul 30, 2025
    😨😨😨 nature.com/articles/s4158…
    82K
  • user avatar
    Paolo Tarantino
    @PTarantinoMD
    Mar 26, 2023
    Reading good review articles can shape ideas, help connecting the dots and understanding what’s coming ahead in science. Here’s 10 review articles that helped me shape my views on breast oncology and drug development:
    123K
  • user avatar
    Paolo Tarantino
    @PTarantinoMD
    Jul 20, 2022
    In 2020 we proposed to add a #HER2Low slice to the HER2 pie chart, an addition that has now entered practice. But further changes await us in the coming years. Excited to share our latest Cancer Discovery piece, outlining the present & future of HER2-low! aacrjournals.org/cancerdiscover…
  • user avatar
    Paolo Tarantino
    @PTarantinoMD
    Oct 22, 2023
    Historical moment for GU oncology. @tompowles1 brilliantly presents the results of the EV-302 phase 3 trial, showing a doubling of OS for patients with mUC receiving 1L enfortumab vedotin+pembro vs SoC platinum-based chemo. ADCs keep shining and improving outcomes! #ESMO23
    00:00
    103K
  • user avatar
    Paolo Tarantino
    @PTarantinoMD
    Jun 4, 2022
    The MRD revolution has started. In this trial (n=455), stage II CRC pts were randomized to standard management or ctDNA-guided (no adj chemo if ctDNA negative). ctDNA guidance halved the use of chemotherapy, preserving outcomes. We need the same in #bcsm! nejm.org/doi/full/10.10…
  • user avatar
    Paolo Tarantino
    @PTarantinoMD
    Nov 14, 2022
    T-DXd has shown remarkable activity for treating HER2-positive and HER2-low breast cancers. However, it may soon expand its reach, and become a treatment option even for HER2-0 tumors. Here’s the 10 reasons why:
  • user avatar
    Paolo Tarantino
    @PTarantinoMD
    May 26, 2022
    In ten days, the presentation of DB-04 may redefine the way we classify and treat breast cancer. Here’s ten HER2-low facts you need to know before attending the ASCO Plenary Session:
  • user avatar
    Paolo Tarantino
    @PTarantinoMD
    Sep 18, 2025
    Adapted to breast oncology #bcsm
    user avatar
    Yüksel Ürün
    @DrYukselUrun
    Sep 18, 2025
    ALK inhibitors in #lungcancer
    57K
  • user avatar
    Paolo Tarantino
    @PTarantinoMD
    Aug 25, 2022
    Two weeks to #ESMO22. Plenty of important breast cancer studies to be presented at the Congress, some that will immediately inform practice. Here’s 10 key abstracts to keep an eye on. See you in Paris! 🇫🇷